<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6356">
  <stage>Registered</stage>
  <submitdate>3/09/2015</submitdate>
  <approvaldate>3/09/2015</approvaldate>
  <nctid>NCT02548962</nctid>
  <trial_identification>
    <studytitle>Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma</studytitle>
    <scientifictitle>A Randomized Multicenter Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>PCI-32765</secondaryid>
    <secondaryid>PCYC-1138-CA</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Multiple Myeloma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Other cancer types</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Ibrutinib
Treatment: drugs - Pomalidomide
Treatment: drugs - Dexamethasone
Treatment: drugs - Placebo

Experimental: Phase 1: Dose Finding - Ibrutinib PO+ Pomalidomide PO+ Dexamethasone PO

Experimental: Phase 2: Treatment Arm A - Ibrutinib PO+ Pomalidomide PO+ Dexamethasone PO

Experimental: Phase 2: Treatment Arm B - Placebo PO+ Pomalidomide PO+ Dexamethasone PO


Treatment: drugs: Ibrutinib


Treatment: drugs: Pomalidomide


Treatment: drugs: Dexamethasone


Treatment: drugs: Placebo


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Phase 1: Safety and tolerability as measured by the number of dose-limiting toxicities (DLT) graded using the NCI CTCAE v 4.03</outcome>
      <timepoint>Up to 12 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Phase 2: Progression Free Survival (PFS) as assessed by the International Myeloma Working Group (IMWG) response criteria.</outcome>
      <timepoint>Up to 24 months after last subject randomized</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Subjects with relapsed/refractory MM who have received at least two prior lines of
             therapy including lenalidomide and either bortezomib or carfilzomib and have
             demonstrated disease progression on or within 60 days of the completion of the most
             recent treatment regimen.

          -  Measurable disease defined by at least ONE of the following:

               1. Serum monoclonal protein (SPEP) =1 g/dL.

               2. Urine monoclonal protein (UPEP) =200 mg by 24 hour urine.

          -  Adequate hematologic, hepatic, and renal function

          -  ECOG performance status of = 2</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>100</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Subject must not have primary refractory disease

          -  Plasma cell leukemia, primary amyloidosis or POEMS syndrome

          -  Unable to swallow capsules or disease significantly affecting gastrointestinal
             function

          -  Requires treatment with strong CYP3A inhibitors

          -  Women who are pregnant or breast feeding.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1/Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>235</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/02/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD</recruitmentstate>
    <hospital>Concord Repatriation General Hospital - Concord</hospital>
    <hospital>Princess Alexandra Hospital - Woolloongabba</hospital>
    <postcode>2139 - Concord</postcode>
    <postcode>4102 - Woolloongabba</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Brno</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Ostrava</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Praha</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Dresden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Attiki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Navarra</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Salamanca</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Pharmacyclics LLC.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Celgene Corporation</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Phase 1 will be an open-label, dose finding, multicenter study of ibrutinib in combination
      with pomalidomide and dexamethasone in subjects with relapsed/refractory multiple myeloma.

      Phase 2b will be conducted as a randomized, double-blind, multicenter study of ibrutinib or
      placebo, in combination with pomalidomide and dexamethasone in subjects with
      relapsed/refractory multiple myeloma.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02548962</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Lipo Chang</name>
      <address />
      <phone>408-215-3437</phone>
      <fax />
      <email>lchang@pcyc.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>